Welcome to our dedicated page for Cidara Theraptcs SEC filings (Ticker: CDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cidara Therapeutics, Inc. (CDTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a former Nasdaq-listed biotechnology issuer. These documents include current reports on Form 8-K, financing-related filings, and other materials that describe Cidara’s clinical development plans, capital structure changes, government agreements, and its acquisition by Merck.
For investors and researchers analyzing Cidara’s business, the company’s 8-K filings are especially important. They detail key events such as the Agreement and Plan of Merger with Merck Sharp & Dohme LLC and a Merck subsidiary, the terms of the cash tender offer for all outstanding shares of common and Series A preferred stock, and the planned merger that will make Cidara a wholly owned subsidiary of Merck. These filings also outline conditions to closing, tender offer mechanics, termination fees, and other transaction terms.
Other 8-K reports describe Cidara’s clinical and regulatory progress with CD388. For example, filings explain updates to the planned Phase 3 registrational trial following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), including expansion of the ANCHOR study population and the intention to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional filings summarize positive topline results from the Phase 2b NAVIGATE trial and provide context on safety and prevention efficacy data.
Cidara’s filings also cover its Award/Contract with the Biomedical Advanced Research and Development Authority (BARDA) to support expanded manufacturing and clinical development of CD388, including base-period funding for onshoring manufacturing to the United States and potential option funding for further studies. Capital markets transactions, such as underwritten public offerings of common stock and suspension of an at-the-market (ATM) prospectus, are documented in 8-Ks that describe underwriting agreements, share issuance, and related legal opinions.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that highlight the main points of each document. Users can quickly see what each 8-K, registration-related filing, or other report means for Cidara’s clinical programs, financing, and merger process. While Cidara’s common stock is expected to cease trading on the Nasdaq Global Market following completion of its merger with Merck, its historical filings remain a key resource for understanding the evolution of CD388, the Cloudbreak platform, and the corporate steps leading to the acquisition.
Cidara Therapeutics (CDTX) reported Q3 2025 results showing a larger operating loss as it advanced its lead antiviral, CD388. The company recorded no revenue and a net loss of $83.2 million, driven by $45.0 million of acquired in‑process R&D and higher R&D spending.
Liquidity strengthened following capital raises. As of September 30, cash and cash equivalents were $293.7 million, with $126.4 million in short‑term and $50.2 million in long‑term available‑for‑sale investments; restricted cash was $6.3 million. In June, the company completed an underwritten offering of 9,147,727 shares at $44.00 per share for net proceeds of $376.9 million, and earlier sold shares via ATM for $4.1 million.
Clinical progress continued. In June, the Phase 2b NAVIGATE study of CD388 met its primary and secondary endpoints across all doses. In September, Cidara initiated the Phase 3 ANCHOR trial evaluating a single 450mg subcutaneous dose for pre‑exposure prophylaxis of seasonal influenza. The company also entered a cost‑reimbursement BARDA contract on September 30. Shares outstanding were 29,335,397 at quarter‑end and 31,439,371 as of November 3, 2025.
Cidara Therapeutics, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025. The company furnished this update through a press release dated November 6, 2025, which is attached as an exhibit to the report. The filing classifies the information as furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other regulatory documents.
Cidara Therapeutics entered a BARDA agreement that can total $339.2M, with an initial investment of approximately $58.1M to begin in September 2025 and run through September 2027. The initial funds will support the onshoring of CD388 manufacturing to U.S. contractors, a clinical trial to show comparability of a higher‑concentration formulation and different presentations, additional non‑clinical characterization against pandemic influenza strains, and development of protocols for expanded populations. BARDA may exercise up to nine options covering further clinical and non‑clinical work totaling up to $281.1M; Cidara may owe up to $192.2M in cost share for up to three of those options. The agreement starts on September 30, 2025, initially runs to September 29, 2027, and may extend but not beyond July 3, 2030. Either party may terminate with 60 days' notice; BARDA may terminate for cause. Some termination costs may be reimbursable by BARDA. The instrument is funded under federal contract 75A50125C00017 and supports Cidara's potential BLA path for CD388. Forward‑looking statements are included and subject to stated risks and uncertainties.
Cidara Therapeutics (CDTX) disclosed details about a clinical evaluation of CD388, specifying a 450-milligram dose versus placebo and a clearly defined primary endpoint based on laboratory-confirmed influenza, measured fever (≥ 37.2°C/99°F) and combinations of respiratory and systemic symptoms. The filing reiterates standard forward-looking statement language and points investors to the company's Quarterly Report for the period ended June 30, 2025 for additional risk factors.
The report emphasizes that outcomes and cash usage may differ from expectations and that the company does not intend to update forward-looking statements except as required by law. The filing is dated September 24, 2025 and is signed by Jeffrey Stein, Ph.D.
Cidara Therapeutics (CDTX) disclosed details about a clinical evaluation of CD388, specifying a 450-milligram dose versus placebo and a clearly defined primary endpoint based on laboratory-confirmed influenza, measured fever (≥ 37.2°C/99°F) and combinations of respiratory and systemic symptoms. The filing reiterates standard forward-looking statement language and points investors to the company's Quarterly Report for the period ended June 30, 2025 for additional risk factors.
The report emphasizes that outcomes and cash usage may differ from expectations and that the company does not intend to update forward-looking statements except as required by law. The filing is dated September 24, 2025 and is signed by Jeffrey Stein, Ph.D.
Cidara Therapeutics insider sale to cover RSU taxes Nicole Davarpanah, the company's Chief Medical Officer, sold 474 shares of Cidara Therapeutics common stock on 09/11/2025 to satisfy tax withholding obligations tied to vested restricted stock units. The weighted-average sale price reported is $62.8627, with transaction prices ranging from $62.86 to $63.50. After the reported sale, the reporting person beneficially owns 31,418 shares; this total includes 200 shares purchased through the company Employee Stock Purchase Plan on May 20, 2025. The Form 4 was executed by an attorney-in-fact on 09/15/2025.
Venrock group reports a 3.2% passive stake in Cidara Therapeutics (CDTX) held collectively as of June 30, 2025. The filing lists 639,088 shares beneficially owned across Venrock entities: 134,554 shares held by Venrock Healthcare Capital Partners III, L.P.; 13,456 by VHCP Co-Investment Holdings III, LLC; and 491,078 by Venrock Healthcare Capital Partners EG, L.P. All reporting entities are Delaware-organized and report shared voting and dispositive power over the 639,088 shares and no sole voting or dispositive power. The percentage is calculated using 20,163,696 shares outstanding per the issuer prospectus supplement dated June 24, 2025. Signatures and powers of attorney are included by reference.
Cidara Therapeutics, Inc. (CDTX) received a Schedule 13G/A reporting that Point72-affiliated entities and Steven A. Cohen beneficially own 1,527,930 shares of common stock, representing 7.6% of the outstanding class as of June 30, 2025. The filing states those shares are held for investment by Point72 Associates and that Point72 Asset Management and Point72 Capital Advisors maintain shared voting and dispositive power over the shares; none of the reporting persons claim sole voting or dispositive power. The reporting address is 72 Cummings Point Road, Stamford, CT.
Canaan XII L.P. and Canaan Partners XII LLC filed Amendment No. 1 to Schedule 13G reporting that, as of June 30, 2025, neither reporting person beneficially owns any shares of Cidara Therapeutics, Inc. common stock (CUSIP 171757206). The filing lists each filer’s jurisdiction of organization and principal business address and states the holders have 0 sole or shared voting and dispositive power, representing 0.0% of the class.
Cidara Therapeutics' Schedule 13G/A discloses that Vivo Opportunity Fund Holdings, L.P. (and its general partner Vivo Opportunity, LLC) beneficially owns 1,175,796 shares of Cidara common stock, representing 4.6% of the outstanding class. Vivo Opportunity Cayman Fund, L.P. (and its general partner Vivo Opportunity Cayman, LLC) beneficially owns 135,629 shares, representing 0.5% of the class. Each reporting person reports sole voting and sole dispositive power over the shares they hold of record through the funds. The filing states the holdings were not acquired to change or influence control of the issuer and ties beneficial ownership to the funds and their general partners as disclosed in the issuer's public filings.
Adage Capital Management and two principals report a passive 4.97% stake in Cidara Therapeutics (CDTX), holding 1,100,000 shares in shared voting and dispositive power. The filings identify Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as the reporting persons and state the position is held in the ordinary course of business and not to influence control. The percentage is calculated on a pro forma share count of 22,117,550 shares, which combines 12,969,823 outstanding shares as of May 5, 2025 and 9,147,727 shares issued under a June 25, 2025 prospectus after full exercise of the over-allotment.
The report shows 0 sole voting/dispositive power and 1,100,000 shares of shared voting/dispositive power, placing the holding under the 5% reporting threshold for greater-than-5% ownership.